In an unusual move, the U.S. Department of Justice and U.S. Patent and Trademark Office submitted a “Statement of Interest” this week in a pending patent case in the Eastern District of Texas—sharing “views” on whether...more
As we head into BIO 2025 in Boston, our teams are closely watching trends in biotech and how those affect financings, business development, IP protection, risk, and litigation strategy. Here are eight key trends we’re...more
6/10/2025
/ Artificial Intelligence ,
Biotechnology ,
Business Development ,
Clinical Trials ,
Data Privacy ,
Intellectual Property Litigation ,
Intellectual Property Protection ,
Life Sciences ,
Litigation Strategies ,
Medical Research ,
Pharmaceutical Industry ,
Regulatory Requirements ,
Research and Development ,
Risk Management ,
Scientific Research ,
Sustainability ,
Vaccinations
On February 28, 2025, the United States Patent and Trademark Office (USPTO) rescinded a June 2022 memorandum clarifying when the Patent Trial and Appeal Board (PTAB) can issue discretionary denials of post-grant patent...more
On Tuesday, the en banc Federal Circuit released its highly anticipated decision in LKQ v. GM Global Technology Operations LLC, rejecting as “improperly rigid” the previous standard for evaluating whether a design patent is...more
5/24/2024
/ Design Patent ,
En Banc Review ,
Intellectual Property Litigation ,
Intellectual Property Protection ,
Inter Partes Review (IPR) Proceeding ,
Obviousness ,
Patent Litigation ,
Patent Prosecution ,
Patent Trial and Appeal Board ,
Patents ,
Precedential Opinion ,
Prior Art ,
USPTO ,
Utility Patents